RARA and acute myeloid leukemia: Our observation of a synergistic induction of differentiation in MOLM13 and OCI-AML3 cells after combined treatment with revumenib and the selective RARalpha agonist tamibarotene demonstrates a high clinical potential for both KMT2Ar- and NPM1c-positive AML patients.